Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study.
Nelli F, Fabbri A, Onorato A, Giannarelli D, Silvestri MA, Pessina G, Giron Berrios JR, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Panichi V, Cercola P, Signorelli C, Chilelli MG, Primi F, Ruggeri EM. Nelli F, et al. Among authors: mazzotta m. Ann Oncol. 2022 Mar;33(3):352-354. doi: 10.1016/j.annonc.2021.12.001. Epub 2021 Dec 10. Ann Oncol. 2022. PMID: 34896598 Free PMC article. No abstract available.
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D, Mazzotta M, Scalera S, Terrenato I, Sperati F, D'Ambrosio L, Pallocca M, Corleone G, Krasniqi E, Pizzuti L, Barba M, Carpano S, Vici P, Filetti M, Giusti R, Vecchione A, Occhipinti M, Gelibter A, Botticelli A, De Nicola F, Ciuffreda L, Goeman F, Gallo E, Visca P, Pescarmona E, Fanciulli M, De Maria R, Marchetti P, Ciliberto G, Maugeri-Saccà M. Marinelli D, et al. Among authors: mazzotta m. Ann Oncol. 2020 Dec;31(12):1746-1754. doi: 10.1016/j.annonc.2020.08.2105. Epub 2020 Aug 28. Ann Oncol. 2020. PMID: 32866624 Free article.
Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study.
Nelli F, Fabbri A, Onorato A, Giannarelli D, Silvestri MA, Giron Berrios JR, Virtuoso A, Marrucci E, Signorelli C, Chilelli MG, Primi F, Schirripa M, Mazzotta M, Ruggeri EM. Nelli F, et al. Among authors: mazzotta m. Ann Oncol. 2022 Jan;33(1):107-108. doi: 10.1016/j.annonc.2021.09.009. Epub 2021 Sep 20. Ann Oncol. 2022. PMID: 34555502 Free PMC article. No abstract available.
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study.
Ruggeri EM, Nelli F, Fabbri A, Onorato A, Giannarelli D, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Panichi V, Pessina G, Signorelli C, Chilelli MG, Primi F, Natoni F, Fazio S, Silvestri MA. Ruggeri EM, et al. Among authors: mazzotta m. ESMO Open. 2022 Feb;7(1):100350. doi: 10.1016/j.esmoop.2021.100350. Epub 2021 Nov 27. ESMO Open. 2022. PMID: 34942438 Free PMC article.
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting.
Pizzuti L, Krasniqi E, Sperduti I, Barba M, Gamucci T, Mauri M, Veltri EM, Meattini I, Berardi R, Di Lisa FS, Natoli C, Pistelli M, Iezzi L, Risi E, D'Ostilio N, Tomao S, Ficorella C, Cannita K, Riccardi F, Cassano A, Bria E, Fabbri MA, Mazzotta M, Barchiesi G, Botticelli A, D'Auria G, Ceribelli A, Michelotti A, Russo A, Salimbeni BT, Sarobba G, Giotta F, Paris I, Saltarelli R, Marinelli D, Corsi D, Capomolla EM, Sini V, Moscetti L, Mentuccia L, Tonini G, Raffaele M, Marchetti L, Minelli M, Ruggeri EM, Scavina P, Bacciu O, Salesi N, Livi L, Tinari N, Grassadonia A, Fedele Scinto A, Rossi R, Valerio MR, Landucci E, Stani S, Fratini B, Maugeri-Saccà M, De Tursi M, Maione A, Santini D, Orlandi A, Lorusso V, Cortesi E, Sanguineti G, Pinnarò P, Cappuzzo F, Landi L, Botti C, Tomao F, Cappelli S, Bon G, Pelle F, Cavicchi F, Fiorio E, Foglietta J, Scagnoli S, Marchetti P, Ciliberto G, Vici P. Pizzuti L, et al. Among authors: mazzotta m. Ther Adv Med Oncol. 2021 Nov 29;13:17588359211059873. doi: 10.1177/17588359211059873. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 35173816 Free PMC article.
Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.
Chilelli MG, Signorelli C, Giron Berrios JR, Onorato A, Nelli F, Fabbri MA, Primi F, Marrucci E, Virtuoso A, Schirripa M, Mazzotta M, Ruggeri EM. Chilelli MG, et al. Among authors: mazzotta m. Cancer Diagn Progn. 2022 Jan 3;2(1):55-63. doi: 10.21873/cdp.10076. eCollection 2022 Jan-Feb. Cancer Diagn Progn. 2022. PMID: 35400002 Free PMC article.
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study.
Nelli F, Giannarelli D, Fabbri A, Silvestri MA, Berrios JRG, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Onorato A, Panichi V, Topini G, Pessina G, Natoni F, Signorelli C, Chilelli MG, Primi F, Ruggeri EM. Nelli F, et al. Among authors: mazzotta m. Ann Oncol. 2022 Jul;33(7):740-742. doi: 10.1016/j.annonc.2022.04.002. Epub 2022 Apr 9. Ann Oncol. 2022. PMID: 35413398 Free PMC article. No abstract available.
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study.
Nelli F, Fabbri A, Panichi V, Giannarelli D, Topini G, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Signorelli C, Chilelli MG, Primi F, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: mazzotta m. Int Immunopharmacol. 2022 Jul;108:108774. doi: 10.1016/j.intimp.2022.108774. Epub 2022 Apr 14. Int Immunopharmacol. 2022. PMID: 35461110 Free PMC article.
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.
Scalera S, Ricciuti B, Mazzotta M, Calonaci N, Alessi JV, Cipriani L, Bon G, Messina B, Lamberti G, Di Federico A, Pecci F, Milite S, Krasniqi E, Barba M, Vici P, Vecchione A, De Nicola F, Ciuffreda L, Goeman F, Fanciulli M, Buglioni S, Pescarmona E, Sharma B, Felt KD, Lindsay J, Rodig SJ, De Maria R, Caravagna G, Cappuzzo F, Ciliberto G, Awad MM, Maugeri-Saccà M. Scalera S, et al. Among authors: mazzotta m. Ann Oncol. 2023 Mar;34(3):275-288. doi: 10.1016/j.annonc.2022.12.002. Epub 2022 Dec 13. Ann Oncol. 2023. PMID: 36526124 Free article.
162 results